Brain Cancer Clinical Trials in Georgia

Showing 41-60 of 166 trials

Atovaquone Combined With Radiation in Children With Malignant Brain Tumors

NCT06624371

The goal of this interventional study is to Assess the safety and tolerability of atovaquone in combination with standard radiation therapy (RT) for the treatment of pediatric patients with newly diagnosed pediatric high-grade glioma/diffuse midline glioma/diffuse intrinsic pontine glioma (pHGG/DMG/DIPG). The secondary aim is to assess the safety and tolerability of longer-term atovaquone treatment for pediatric patients with relapsed or progressed pHGG/DMG/DIPG and medulloblastoma (MB) or pHGG/DMG/DIPG after completion of RT and before progression.

High-grade GliomaMedulloblastomaDiffuse Intrinsic Pontine Glioma+1 more

Emory University18 participantsStarted Mar 2025

Atlanta, Georgia, United States • Atlanta, Georgia, United States

Active Not RecruitingPhase 2/365 miles

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

NCT05685004

This randomized study is designed to compare the combination of TVI-Brain-1 immunotherapy and standard therapy compared to standard therapy alone as a treatment for newly diagnosed MGMT unmethylated glioblastoma patients. The patients' own cancer cells collected after surgery are combined into a vaccine to produce an immune response that significantly increases the number of cancer neoantigen-specific effector T cell precursors in the patient's body. These cancer neoantigen-specific T cells are harvested from the blood, subsequently stimulated and expanded, and infused back into the patient.

Glioblastoma Multiforme of Brain

TVAX Biomedical120 participantsStarted Sep 2023

Tucson, Arizona, United States • Los Angeles, California, United States • Los Angeles, California, United States +5 more locations

Atovaquone Combined With Radiation in Children With Malignant Brain Tumors

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

Brain Cancer Trials in Other Cities

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

9-ING-41 in Pediatric Patients With Refractory Malignancies.

A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System

Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Safety and Effectiveness of Blood-Brain Barrier Disruption (BBBD) in Subjects With Suspected Infiltrating Glioma

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma

Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma

VB-111 in Surgically Accessible Recurrent/Progressive GBM

Other Conditions in Georgia